Business Description
GENinCode PLC
ISIN : GB00BL97B504
Total Employee Number:
36Description
GENinCode PLC principal activity is the development and commercialisation of clinical genetic tests, to provide predictive analysis of risk to a patient's health based on their genes. The company has one operating segment. The company has presence in Spain, UK, United States, Italy, Germany, and Rest of World. The company generates majority of revenue from Spain. Its commercial products are CE-Marked, with CARDIO inCode, THROMBO inCode, and LIPID inCode.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.13 | |||||
Equity-to-Asset | 0.05 | |||||
Debt-to-Equity | 1.18 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -20.21 | |||||
Beneish M-Score | -5.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.8 | |||||
3-Year EBITDA Growth Rate | 29.9 | |||||
3-Year EPS without NRI Growth Rate | 28.7 | |||||
3-Year FCF Growth Rate | 32.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.38 | |||||
9-Day RSI | 44.87 | |||||
14-Day RSI | 46.49 | |||||
6-1 Month Momentum % | -97.22 | |||||
12-1 Month Momentum % | -95.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.93 | |||||
Quick Ratio | 0.9 | |||||
Cash Ratio | 0.41 | |||||
Days Inventory | 28.12 | |||||
Days Sales Outstanding | 103.87 | |||||
Days Payable | 310.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -44.1 | |||||
Shareholder Yield % | -54.06 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 58.65 | |||||
Operating Margin % | -183.65 | |||||
Net Margin % | -185.47 | |||||
EBITDA Margin % | -181.53 | |||||
FCF Margin % | -135.04 | |||||
OCF Margin % | -135.04 | |||||
ROE % | -437.28 | |||||
ROA % | -184.81 | |||||
ROIC % | -636.44 | |||||
3-Year ROIIC % | -25.96 | |||||
ROC (Joel Greenblatt) % | -1820.54 | |||||
ROCE % | -406.53 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.82 | |||||
EV-to-EBIT | -1 | |||||
EV-to-Forward-EBIT | -1.18 | |||||
EV-to-EBITDA | -1.05 | |||||
EV-to-Forward-EBITDA | -1.49 | |||||
EV-to-Revenue | 1.9 | |||||
EV-to-Forward-Revenue | 1.27 | |||||
EV-to-FCF | -1.46 | |||||
Earnings Yield (Greenblatt) % | -100.22 | |||||
FCF Yield % | -62.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GENinCode PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3.57 | ||
| EPS (TTM) (€) | -0.024 | ||
| Beta | 6.4869 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 3.34 | ||
| Volatility % | 1014.06 | ||
| 14-Day RSI | 46.49 | ||
| 14-Day ATR (€) | 0.001714 | ||
| 20-Day SMA (€) | 0.0005 | ||
| 12-1 Month Momentum % | -95.24 | ||
| 52-Week Range (€) | 0.0005 - 0.054 | ||
| Shares Outstanding (Mil) | 753.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GENinCode PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GENinCode PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-10-02 10:00 | In 87 days | ||
| Second quarter earnings results for 2026 | 2026-09-30 | In 84 days | ||
| General meeting for 2026 | 2026-07-01 10:00 | 0.00 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-06-10 10:00 | 0.00 (+0.00%) | ||
| Annual report for 2025 | 2026-06-08 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-06-08 | 0.00 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-10-02 10:00 | 0.03 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-30 | 0.04 (-2.60%) | ||
| General meeting for 2024 | 2025-06-30 10:00 | 0.02 (+0.00%) | ||
| Fourth quarter earnings conference call for 2024 | 2025-06-04 09:30 | 0.01 (+0.00%) |
Show
Entries
GENinCode PLC Frequently Asked Questions
What is GENinCode PLC(STU:9PL)'s stock price today?
The current price of STU:9PL is €0.00. The 52 week high of STU:9PL is €0.05 and 52 week low is €0.00.
When is next earnings date of GENinCode PLC(STU:9PL)?
The next earnings date of GENinCode PLC(STU:9PL) is 2026-09-30 Est..
Does GENinCode PLC(STU:9PL) pay dividends? If so, how much?
GENinCode PLC(STU:9PL) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| New Study From GENinCode Shows Polygenic Risk Scores Improve the Accuracy of Cardiovascular Disease Risk Prediction | 2025-11-12 |
Articles on GENinCode PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers